FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 21 08 2018
accepted: 23 12 2018
entrez: 18 1 2019
pubmed: 18 1 2019
medline: 19 11 2019
Statut: epublish

Résumé

During erythropoiesis, haematopoietic stem cells (HSCs) differentiate in successive steps of commitment and specification to mature erythrocytes. This differentiation process is controlled by transcription factors that establish stage- and cell type-specific gene expression. In this study, we demonstrate that FUSE binding protein 1 (FUBP1), a transcriptional regulator important for HSC self-renewal and survival, is regulated by T-cell acute lymphocytic leukaemia 1 (TAL1) in erythroid progenitor cells. TAL1 directly activates the FUBP1 promoter, leading to increased FUBP1 expression during erythroid differentiation. The binding of TAL1 to the FUBP1 promoter is highly dependent on an intact GATA sequence in a combined E-box/GATA motif. We found that FUBP1 expression is required for efficient erythropoiesis, as FUBP1-deficient progenitor cells were limited in their potential of erythroid differentiation. Thus, the finding of an interconnection between GATA1/TAL1 and FUBP1 reveals a molecular mechanism that is part of the switch from progenitor- to erythrocyte-specific gene expression. In summary, we identified a TAL1/FUBP1 transcriptional relationship, whose physiological function in haematopoiesis is connected to proper erythropoiesis.

Identifiants

pubmed: 30653565
doi: 10.1371/journal.pone.0210515
pii: PONE-D-18-24611
pmc: PMC6336336
doi:

Substances chimiques

DNA-Binding Proteins 0
FUBP1 protein, human 0
GATA1 Transcription Factor 0
GATA1 protein, human 0
RNA-Binding Proteins 0
T-Cell Acute Lymphocytic Leukemia Protein 1 0
TAL1 protein, human 135471-20-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0210515

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Blood. 2017 Apr 13;129(15):2051-2060
pubmed: 28179281
J Biol Chem. 2010 Dec 17;285(51):40252-65
pubmed: 20940306
Blood. 2008 Aug 15;112(4):1056-67
pubmed: 18550854
Semin Immunol. 2008 Aug;20(4):257-63
pubmed: 18579409
Stem Cells Int. 2017;2017:5762301
pubmed: 28588622
Hepatology. 2009 Oct;50(4):1121-9
pubmed: 19637194
Genes Cells. 2013 Nov;18(11):921-33
pubmed: 23911012
Mol Cell Biol. 2015 Oct 26;36(1):157-72
pubmed: 26503782
Nature. 2018 Mar 1;555(7694):54-60
pubmed: 29466336
Br J Haematol. 2006 Oct;135(1):117-28
pubmed: 16965383
Science. 1999 Jan 29;283(5402):676-9
pubmed: 9924025
Haematologica. 2018 Jan;103(1):18-29
pubmed: 29025910
Development. 1995 Jan;121(1):163-72
pubmed: 7867497
BMC Cancer. 2014 Dec 08;14:925
pubmed: 25487856
Curr Top Dev Biol. 2016;118:163-204
pubmed: 27137657
Int J Biochem Cell Biol. 2011 Nov;43(11):1641-8
pubmed: 21855647
EMBO J. 2011 Mar 2;30(5):846-58
pubmed: 21285945
Eur J Biochem. 2002 Aug;269(15):3607-18
pubmed: 12153557
Nature. 1995 Feb 2;373(6513):432-4
pubmed: 7830794
Cell Rep. 2015 Jun 30;11(12):1847-55
pubmed: 26095368
Mol Cell Biol. 2006 Mar;26(6):2373-86
pubmed: 16508012
Cell Death Differ. 2015 May;22(5):790-800
pubmed: 25323585
Blood. 2010 Jan 28;115(4):792-803
pubmed: 19850742
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17413-8
pubmed: 19805084
Mol Cell Biol. 2005 Aug;25(15):6355-62
pubmed: 16024775
Nucleic Acids Res. 2014 Jan;42(Database issue):D172-7
pubmed: 24185696
Oncogene. 2002 May 13;21(21):3368-76
pubmed: 12032775
Mol Cells. 2005 Oct 31;20(2):157-66
pubmed: 16267388
IUBMB Life. 2009 Aug;61(8):800-30
pubmed: 19621348
Curr Top Dev Biol. 2016;118:45-76
pubmed: 27137654
Blood. 2009 Mar 5;113(10):2191-201
pubmed: 19011221
Trends Genet. 2014 Jan;30(1):1-9
pubmed: 24290192
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8
pubmed: 8901585
Mol Cell Biol. 2007 Jun;27(12):4551-65
pubmed: 17438135
Oncogene. 2013 Jun 13;32(24):2907-16
pubmed: 22926519
Oncogene. 2013 May 16;32(20):2565-75
pubmed: 22777353
Genome Res. 2014 Dec;24(12):1945-62
pubmed: 25319994
J Biol Chem. 1996 Dec 6;271(49):31679-87
pubmed: 8940189
J Mol Med (Berl). 2006 Nov;84(11):901-10
pubmed: 16972087
Blood. 2015 Jun 4;125(23):3570-9
pubmed: 25911237
Cell Rep. 2016 Jun 14;15(11):2550-62
pubmed: 27264182
Clin Lab Med. 2015 Mar;35(1):43-57
pubmed: 25676371
Nature. 2018 Jan 11;553(7687):212-216
pubmed: 29323290
EMBO J. 1996 Aug 15;15(16):4123-9
pubmed: 8861941
Bone. 2019 Feb;119:36-41
pubmed: 29551752

Auteurs

Marlene Steiner (M)

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt/Main, Germany.

Lucas Schneider (L)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Jasmin Yillah (J)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Katharina Gerlach (K)

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt/Main, Germany.

Olga N Kuvardina (ON)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Annekarin Meyer (A)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Alisa Maring (A)

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt/Main, Germany.

Halvard Bonig (H)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Erhard Seifried (E)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Martin Zörnig (M)

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt/Main, Germany.

Jörn Lausen (J)

Institute for Transfusion Medicine and Immunohematology, Goethe-University and German Red Cross Blood Service, Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH